| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Submitted by Anonymous (not verified) on 8 December 2023 - 16:21

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 8 December 2023 - 16:10

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

Submitted by Anonymous (not verified) on 8 December 2023 - 16:02

Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised

Submitted by Anonymous (not verified) on 8 December 2023 - 15:48

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Spravato, esketamine, Date of authorisation: 18/12/2019, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 8 December 2023 - 15:44

Human medicines European public assessment report (EPAR): Spravato, esketamine, Date of authorisation: 18/12/2019, Revision: 9, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Spravato, esketamine, Date of authorisation: 18/12/2019, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Zilbrysq, Zilucoplan, Date of authorisation: 01/12/2023, Status: Authorised

Submitted by Anonymous (not verified) on 8 December 2023 - 15:36

Human medicines European public assessment report (EPAR): Zilbrysq, Zilucoplan, Date of authorisation: 01/12/2023, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Zilbrysq, Zilucoplan, Date of authorisation: 01/12/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Submitted by Anonymous (not verified) on 8 December 2023 - 15:33

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Summary of opinion: Frontpro (previously known as Afoxolaner Merial), 07/12/2023 Positive

Submitted by Anonymous (not verified) on 8 December 2023 - 15:00

Summary of opinion: Frontpro (previously known as Afoxolaner Merial), 07/12/2023 Positive

Read more about Summary of opinion: Frontpro (previously known as Afoxolaner Merial), 07/12/2023 Positive

Procurement

Submitted by Anonymous (not verified) on 8 December 2023 - 14:54

Procurement

Read more about Procurement

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Atriance, nelarabine, Date of authorisation: 22/08/2007, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Faslodex, fulvestrant, Date of authorisation: 09/03/2004, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Spravato, esketamine, Date of authorisation: 18/12/2019, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Zilbrysq, Zilucoplan, Date of authorisation: 01/12/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 19, Status: Authorised

Summary of opinion: Frontpro (previously known as Afoxolaner Merial), 07/12/2023 Positive

Procurement

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters